Found: 56
Select item for more details and to access through your institution.
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 619, doi. 10.1007/s10637-017-0531-3
- By:
- Publication type:
- Article
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. E423, doi. 10.1002/ajh.26319
- By:
- Publication type:
- Article
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 5, p. E86, doi. 10.1002/ajh.23967
- By:
- Publication type:
- Article
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 4, p. 314, doi. 10.1002/ajh.23933
- By:
- Publication type:
- Article
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 1, p. 42, doi. 10.1002/ajh.23868
- By:
- Publication type:
- Article
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.
- Published in:
- Cells (2073-4409), 2024, v. 13, n. 10, p. 879, doi. 10.3390/cells13100879
- By:
- Publication type:
- Article
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 12, p. 1522, doi. 10.3390/cells8121522
- By:
- Publication type:
- Article
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 5, p. 504, doi. 10.1111/ejh.13835
- By:
- Publication type:
- Article
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 6, p. 494, doi. 10.1111/ejh.13231
- By:
- Publication type:
- Article
Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 4, p. 556, doi. 10.1111/ejh.13147
- By:
- Publication type:
- Article
Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 3, p. 269, doi. 10.1111/ejh.12829
- By:
- Publication type:
- Article
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.
- Published in:
- Journal of Blood Medicine, 2017, v. 8, p. 107, doi. 10.2147/JBM.S102328
- By:
- Publication type:
- Article
Cluster-10 lung-cancer antibodies recognize NSPs, novel neuro-endocrine proteins associated with membranes of the endoplasmic reticulum.
- Published in:
- International Journal of Cancer, 1994, v. 57, p. 84, doi. 10.1002/ijc.2910570718
- By:
- Publication type:
- Article
Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153]
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 424, doi. 10.1016/j.clml.2022.03.009
- By:
- Publication type:
- Article
P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S159, doi. 10.1016/S2152-2650(21)02344-2
- By:
- Publication type:
- Article
P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S152, doi. 10.1016/S2152-2650(21)02334-X
- By:
- Publication type:
- Article
P-196: Isatuximab plus Carfilzomib and Dexamethasone in patients with relapsed Multiple Myeloma and soft-tissue Plasmacytomas: IKEMA subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S145, doi. 10.1016/S2152-2650(21)02323-5
- By:
- Publication type:
- Article
MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S423, doi. 10.1016/S2152-2650(21)01948-0
- By:
- Publication type:
- Article
Poster: MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01572-X
- By:
- Publication type:
- Article
Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e254, doi. 10.1016/j.clml.2019.09.420
- By:
- Publication type:
- Article
ICARIA-MM study: efficacy analysis according to prior lines of treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e245, doi. 10.1016/j.clml.2019.09.407
- By:
- Publication type:
- Article
Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e33, doi. 10.1016/j.clml.2019.09.049
- By:
- Publication type:
- Article
The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S337, doi. 10.1016/j.clml.2017.07.153
- By:
- Publication type:
- Article
Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e67, doi. 10.1016/j.clml.2017.03.121
- By:
- Publication type:
- Article
Late vs Early Response and Depth of Response Are Associated with Improved Outcomes: Post-hoc Analysis of Phase 3 TOURMALINE-MM1 Trial (NCT01564537) in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e124, doi. 10.1016/j.clml.2017.03.226
- By:
- Publication type:
- Article
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 3, p. 357, doi. 10.1111/bjh.12266
- By:
- Publication type:
- Article
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
- Published in:
- British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x
- By:
- Publication type:
- Article
The Cost-Effectiveness of Initial Treatment of Multiple Myelomain the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide...
- Published in:
- Oncologist, 2013, v. 18, n. 1, p. 27, doi. 10.1634/theoncologist.2011-0380
- By:
- Publication type:
- Article
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
- Published in:
- European Journal of Haematology, 2012, v. 89, n. 1, p. 16, doi. 10.1111/j.1600-0609.2012.01788.x
- By:
- Publication type:
- Article
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
- By:
- Publication type:
- Article
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
- By:
- Publication type:
- Article
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 120, doi. 10.1111/bjh.17499
- By:
- Publication type:
- Article
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 4, p. 547, doi. 10.1111/bjh.14708
- By:
- Publication type:
- Article
The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 3, p. 368, doi. 10.1111/bjh.14058
- By:
- Publication type:
- Article
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 3, p. 344, doi. 10.1111/bjh.13582
- By:
- Publication type:
- Article
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 1, p. 39, doi. 10.1111/bjh.12717
- By:
- Publication type:
- Article
Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice.
- Published in:
- Health Science Reports, 2019, v. 2, n. 1, p. N.PAG, doi. 10.1002/hsr2.104
- By:
- Publication type:
- Article
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 1, p. 114, doi. 10.1002/jcph.987
- By:
- Publication type:
- Article
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 20, p. 20332, doi. 10.1002/cam4.6619
- By:
- Publication type:
- Article
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753
- By:
- Publication type:
- Article
Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.
- Published in:
- British Journal of Clinical Pharmacology, 2015, v. 80, n. 4, p. 687, doi. 10.1111/bcp.12652
- By:
- Publication type:
- Article
Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 5, p. 2052, doi. 10.1111/bcp.15123
- By:
- Publication type:
- Article
Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma.
- Published in:
- Clinical Pharmacokinetics, 2012, v. 51, n. 12, p. 823, doi. 10.1007/s40262-012-0010-0
- By:
- Publication type:
- Article
Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.
- Published in:
- Clinical Pharmacokinetics, 2011, v. 50, n. 12, p. 781, doi. 10.2165/11594410-000000000-00000
- By:
- Publication type:
- Article
Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile.
- Published in:
- AAPS PharmSciTech, 2011, v. 12, n. 2, p. 461, doi. 10.1208/s12249-010-9554-1
- By:
- Publication type:
- Article
Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 2, p. 376, doi. 10.1002/cpt.1047
- By:
- Publication type:
- Article
Dose selection of siltuximab for multicentric Castleman's disease.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 1037, doi. 10.1007/s00280-015-2720-0
- By:
- Publication type:
- Article
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 1, p. 35, doi. 10.1007/s00280-013-2314-7
- By:
- Publication type:
- Article